2017 ACVIM Forum Research Abstract Program

This study confirmed that MPA reliably inhibits canine B and T cell proliferation in a concentration-dependent fashion, and that IC 50 is achieved at MPA concentrations that are readily achievable at standard MMF dose rates. Based on the results of this in vitro study, oral MMF would be anticipated to have the potential to inhibit both B and T cell proliferation in dogs. Based on the results of our study, the CD4 cell activation assay was not significantly affected by exposure to MPA, suggesting that the assay, although marketed in human medicine as a non-specific test of drug-induced suppression of CD4 positive T cells, may not be of clinical value in dogs receiving MMF. Mycophenolate mofetil (MMF) is an attractive, alternative, commercially available immunosuppressant with a rapid onset of action and minimal side-effects. Our goal in this study was to evaluate the pharmacokinetics (PK), and various clinical parameters after 1 week of oral dosing of MMF in healthy cats. The PK of mycophenolic acid (MPA), the active form of MMF, was evaluated following oral administration of 10 mg/kg PO BID (n = 3), 15 mg/kg PO BID (n = 3), and 15 mg/kg PO TID (n = 4) of MMF (CellCept Ã’ oral suspension, Roche Lab Inc.) for 1 week to a healthy population of cats. Plasma samples were taken prior to the first administration of MMF and at 0.25, 0.5 1, 1.5, 3, 6, 8, 10, 12 hs after the first MMF administration. In addition, plasma samples were taken 24, 72, 121, 145, 157 hs after the first administration (before the next dose).